FTLF FITLIFE BRANDS, INC.
Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1374328 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY46.5%
TTM net income YoY1.9%
TTM EPS YoY1.5%
Revenue 3-yr CAGR32.2%
Net income 3-yr CAGR17.1%
Margins
Gross margin36.7%
Operating margin11.0%
Net margin6.7%
FCF margin4.5%
EBITDA margin11.9%
Returns
ROE15.1%
ROA6.4%
ROIC (approx.)13.8%
Asset turnover0.96x
Leverage & solvency
Liabilities / assets53.3%
Debt / equity0.00x
Current ratio1.64x
Interest coverage3.93x
Cash quality & payout
Operating cash flow / net income0.68x
Accruals ratio2.0%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $81.46M | $64.47M |
| Cost of revenue | $50.01M | $36.39M |
| Gross profit | $31.45M | $28.08M |
| SG&A expense | $14.04M | $9.97M |
| Operating income | $10.06M | $13.12M |
| Interest expense | $1.86M | $1.37M |
| Pretax income | $8.23M | $11.87M |
| Income tax | $1.90M | $2.89M |
| Net income | $6.33M | $8.98M |
| EBITDA | $10.48M | $13.23M |
| EPS (basic) | 0.68 | 0.98 |
| EPS (diluted) | 0.63 | 0.91 |
| Weighted avg. shares (diluted) | 9.98M | 9.90M |
| Balance sheet | ||
| Cash & equivalents | $1.65M | $4.47M |
| Receivables | $8.77M | $1.63M |
| Inventory | $21.32M | $11.07M |
| Current assets | $33.07M | $18.14M |
| PP&E, net | $128,000 | $75,000 |
| Goodwill | $19.39M | $13.02M |
| Intangibles | $51.44M | $26.23M |
| Total assets | $106.32M | $58.53M |
| Current liabilities | $21.61M | $11.31M |
| Short-term debt | — | $4.50M |
| Long-term debt | — | $8.55M |
| Total debt | — | $13.05M |
| Total liabilities | $62.68M | $22.41M |
| Shareholders' equity | $43.64M | $36.13M |
| Net debt | — | $8.58M |
| Shares outstanding | 9.39M | 9.21M |
| Cash flow statement | ||
| Operating cash flow | $7.44M | $9.61M |
| Capital expenditure | $42,000 | $10,000 |
| Free cash flow | $7.40M | $9.60M |
| Investing cash flow | -$42.54M | -$10,000 |
| Financing cash flow | $32.09M | -$6.98M |
| Depreciation & amortization | $420,000 | $108,000 |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.